奥浦迈: 国泰海通证券股份有限公司关于上海奥浦迈生物科技股份有限公司本次交易产业政策和交易类型之独立财务顾问核查意见

Group 1 - The transaction involves Shanghai Aopumai Biotechnology Co., Ltd. acquiring 100% equity of Pengli Bio-pharmaceutical Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment [1][2] - The industry classification of the target company falls under "M73 Scientific Research and Technical Services" specifically within "4.1 Biopharmaceutical Industry" [1][2] - The transaction is categorized as a vertical merger within the same industry, enhancing the company's CRDMO (Cell Culture Medium + Clinical CRO + Biopharmaceutical CDMO) service capabilities [2][3] Group 2 - The transaction includes issuing shares to no more than 35 specific investors to raise supporting funds [3] - The independent financial advisor confirms that the listed company is not under investigation by the China Securities Regulatory Commission (CSRC) [3]